Clinical development of new formulations of cytotoxics in solid tumors

Current Opinion in Oncology
Hatem A Azim, Ahmad Awada

Abstract

To discuss the clinical development of new formulations of old cytotoxic agents and highlight the value of adopting this strategy. Several drugs are currently in clinical development with high potential in improving clinical outcomes compared with their older counterparts. We emphasize on the results of four of these agents, each belonging to a known group of cytotoxics namely amrubicin, EndoTAG-1, pralatrexate and NKTR-102. Each has shown promising results that have the potential in addressing some limitations that have been observed with the 'earlier generation' agents. Improvement in drug development strategies and the appreciation of the mechanisms of action and resistance of the cytotoxic agents currently available in the clinic open the door for developing agents that have the potential of improving clinical outcomes with better safety profiles. It is important to adopt innovative clinical trials designs integrating molecular markers in early clinical development in order to identify the subgroups of patients who would derive the maximal benefit of these novel agents.

References

Jun 1, 1989·Cancer Treatment Reviews·R Perez-Soler
Apr 29, 1998·The Journal of Clinical Investigation·G ThurstonD M McDonald
Dec 16, 1998·Japanese Journal of Cancer Research : Gann·T NoguchiY Yanagi
Dec 16, 1998·Japanese Journal of Cancer Research : Gann·T NoguchiY Yanagi
Aug 17, 1999·Annual Review of Nutrition·F M Sirotnak, B Tolner
Aug 31, 2001·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·H GelderblomA Sparreboom
Jan 25, 2002·The New England Journal of Medicine·Bertrand CoiffierChristian Gisselbrecht
Apr 1, 2004·International Journal of Cancer. Journal International Du Cancer·Sebastian StriethMarc Dellian
Oct 21, 2005·The New England Journal of Medicine·Martine J Piccart-GebhartUNKNOWN Herceptin Adjuvant (HERA) Trial Study Team
Dec 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sayaka OnodaUNKNOWN Thoracic Oncology Research Group Study 0301
Jan 30, 2007·Breast Cancer Research and Treatment·Edurne ArriolaJorge S Reis-Filho
Feb 1, 2007·Anti-cancer Drugs·Hatem A Azim, Apar Kishor Ganti
Apr 6, 2007·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Lee M KrugF M Sirotnak
May 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Christopher G AzzoliF M Sirotnak
Oct 6, 2007·International Journal of Cancer. Journal International Du Cancer·Sebastian StriethMarc Dellian
Jul 17, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sebastian StriethMarc Dellian
Oct 16, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Akira InoueToshihiro Nukiwa
Oct 24, 2008·The New England Journal of Medicine·Christos S KarapetisJohn R Zalcberg
Apr 1, 2009·Expert Opinion on Drug Metabolism & Toxicology·Viet Hong PhanStephen J Clarke
Apr 25, 2009·Nature Reviews. Clinical Oncology·Nagahiro SaijoHideo Kunitoh
Aug 21, 2009·The New England Journal of Medicine·Tony S MokMasahiro Fukuoka
Aug 22, 2009·International Journal of Cancer. Journal International Du Cancer·Martin E EichhornMarc Dellian
Nov 4, 2009·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Hiroyasu KanedaUNKNOWN West Japan Thoracic Oncology Group
Apr 14, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David S EttingerJennifer W Oliver
Dec 8, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert JotteJennifer W Oliver
Jan 20, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Owen A O'ConnorSteven Horwitz
Mar 4, 2011·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Chung-Yu ChenPan-Chyr Yang
Mar 23, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christine DesmedtChristos Sotiriou
Jun 4, 2011·Japanese Journal of Clinical Oncology·Hiroshi YoshidaTomohide Tamura
Jun 21, 2011·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Mary E R O'BrienPaul Baas

❮ Previous
Next ❯

Citations

Mar 21, 2013·Breast Cancer Research and Treatment·Iben KümlerDorte L Nielsen
Mar 29, 2014·BioMed Research International·Su-Eon JinSoon-Sun Hong
May 20, 2015·ACS Biomaterials Science & Engineering·Asiri Ediriwickrema, W Mark Saltzman
Oct 12, 2013·CA: a Cancer Journal for Clinicians·Avnesh S Thakor, Sanjiv S Gambhir

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.